華領醫藥SEED研究者將在CBIIC大會上公佈有關糖尿病緩解的重要研究結果
格隆匯9月23日丨華領醫藥(2552.HK)宣佈,在第六屆中國醫藥創新與投資大會(The China BioMed Innovation and Investment Conference)上,參與華領醫藥播種研究(SEED,又稱HMM0301)的部分研究者將公佈一項名為DREAM的臨牀研究結果,該研究將顯示華領醫藥全球首創新藥葡萄糖激酶激活劑多格列艾汀(dorzagliatin)的持續療效和糖尿病緩解情況。DREAM研究的主要目的是評估SEED研究完成後,經過多格列艾汀治療的部分患者,在不服用降糖藥物情況下的血糖維持情況和胰島β細胞功能改善情況。華領醫藥完成的兩項III期註冊臨牀試驗已經顯示,多格列艾汀在臨牀治療期間表現出長期穩定療效和良好的安全性,有效改善胰島素首相分泌失調、提高β細胞功能和降低胰島素抵抗。DREAM研究的結果有望進一步引發醫療界對於“糖尿病緩解”的積極探索,並有望為2型糖尿病治療帶來全新方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.